The Minnesota grading system using fundus autofluorescence of eye bank eyes: A correlation to age-related macular degeneration (An AOS thesis)

Transactions of the American Ophthalmological Society

Volumn 106, Issue , 2008, Pages 383-401

  Olsen, Timothy W ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; AUTOFLUORESCENCE; COMPUTER PROGRAM; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DNA TEMPLATE; EYEBANK; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OPHTHALMOSCOPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; AGING; CHEMISTRY; CLASSIFICATION; DIAGNOSTIC IMAGING; DONOR; EYE FUNDUS; FLUORESCENCE; METHODOLOGY; MIDDLE AGED; OPHTHALMOSCOPE; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA MACULA DEGENERATION; RETINA MACULA LUTEA;

A2 E (N RETINYLIDENE N RETINYLETHANOLAMINE); A2-E (N-RETINYLIDENE-N-RETINYLETHANOLAMINE); LIPOFUSCIN; RETINOID; VISUAL PIGMENT;

ADULT; AGED; AGED, 80 AND OVER; AGING; DIAGNOSTIC IMAGING; EYE BANKS; FLUORESCENCE; FUNDUS OCULI; HUMANS; LIPOFUSCIN; MACULA LUTEA; MACULAR DEGENERATION; MIDDLE AGED; OPHTHALMOSCOPES; RETINAL PIGMENTS; RETINOIDS; TISSUE DONORS;

EID: 63049126349     PISSN: None     EISSN: 15456110     Source Type: Journal    
DOI: None     Document Type: Article

References (109)

1. Buch H, Vinding T, La Cour M, Appleyard M, Jensen GB, Nielsen NV. Prevalence and causes of visual impairment and blindness among 9980 Scandinavian adults: The Copenhagen City Eye Study. Ophthalmology 2004;111:53-61.
2. Buch H, Vinding T, Nielsen NV. Prevalence and causes of visual impairment according to World Health Organization and United States criteria in an aged, urban Scandinavian population: the Copenhagen City Eye Study. Ophthalmology 2001;108:2347-2357.
3. Klaver CC, Wolfs RC, Vingerling JR, Hofman A, de Jong PT. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 1998;116:653-658.
4. O'Shea JG. Age-related macular degeneration: a leading cause of blindness [see comments]. Med J Aust 1996;165:561-564.
5. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995;102:1450-1460.
6. Klein R, Wang Q, Klein BE, Moss SE, Meuer SM. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci 1995;36:182-191.
7. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99:933-943.
8. Hyman LG, Lilienfeld AM, Ferris FLd, Fine SL. Senile macular degeneration: a case-control study. Am J Epidemiol 1983;118:213-227.
9. Klein BE, Klein R. Cataracts and macular degeneration in older Americans. Arch Ophthalmol 1982;100:571-573.
10. Leibowitz HM, Krueger DE, Maunder LR, et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol 1980;24:335-610.
11. Klein R. Overview of progress in the epidemiology of age-related macular degeneration. Ophthalmic Epidemiol 2007;14:184-187.
12. Wang JJ, Rochtchina E, Lee AJ, et al. Ten-year incidence and progression of age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology 2007;114:92-98.
13. Topouzis F, Coleman AL, Harris A, et al. Prevalence of age-related macular degeneration in Greece: the Thessaloniki Eye Study. Am J Ophthalmol 2006;142:1076-1079.
14. Bandello F, Lafuma A, Berdeaux G. Public health impact of neovascular age-related macular degeneration treatments extrapolated from visual acuity. Invest Ophthalmol Vis Sci 2007;48:96-103.
15. The AREDS Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-1436.
16. Olsen TW, Feng X. The Minnesota Grading System of eye bank eyes for age-related macular degeneration. Invest Ophthalmol Vis Sci 2004;45:4484-4490.
17. Ethen CM, Feng X, Olsen TW, Ferrington DA. Declines in arrestin and rhodopsin in the macula with progression of age-related macular degeneration. Invest Ophthalmol Vis Sci 2005;46:769-775.
18. Ethen CM, Reilly C, Feng X, Olsen TW, Ferrington DA. The proteome of central and peripheral retina with progression of age-related macular degeneration. Invest Ophthalmol Vis Sci 2006;47:2280-2290.
19. Kapphahn RJ, Giwa BM, Berg KM, et al. Retinal proteins modified by 4-hydroxynonenal: identification of molecular targets. Exp Eye Res 2006;83:165-175.
20. Nordgaard CL, Berg KM, Kapphahn RJ, et al. Proteomics of the retinal pigment epithelium reveals altered protein expression at progressive stages of age-related macular degeneration. Invest Ophthalmol Vis Sci 2006;47:815-822.
21. Decanini A, Nordgaard CL, Feng X, Ferrington DA, Olsen TW. Changes in select redox proteins of the retinal pigment epithelium in age-related macular degeneration. Am J Ophthalmol 2007;143:607-615.
22. Ethen CM, Hussong SA, Reilly C, Feng X, Olsen TW, Ferrington DA. Transformation of the proteasome with age-related macular degeneration. FEBS Lett 2007;581:885-890.
23. Ethen CM, Reilly C, Feng X, Olsen TW, Ferrington DA. Age-related macular degeneration and retinal protein modification by 4-hydroxy-2-nonenal. Invest Ophthalmol Vis Sci 2007;48:3469-3479.
24. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
25. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
26. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
27. Jiang S, Moriarty-Craige SE, Orr M, Cai J, Sternberg P Jr, Jones DP. Oxidant-induced apoptosis in human retinal pigment epithelial cells: dependence on extracellular redox state. Invest Ophthalmol Vis Sci 2005;46:1054-1061.
28. Yang P, Wiser JL, Peairs JJ, et al. Human RPE expression of cell survival factors. Invest Ophthalmol Vis Sci 2005;46:1755-1764.
29. Choudhary S, Xiao T, Srivastava S, et al. Toxicity and detoxification of lipid-derived aldehydes in cultured retinal pigmented epithelial cells. Toxicol Appl Pharmacol 2005;204:122-134.
30. Howes KA, Liu Y, Dunaief JL, et al. Receptor for advanced glycation end products and age-related macular degeneration. Invest Ophthalmol Vis Sci 2004;45:3713-3720.
31. Chen L, Wu W, Dentchev T, et al. Light damage induced changes in mouse retinal gene expression. Exp Eye Res 2004;79:239-247.
32. Takahashi A, Masuda A, Sun M, Centonze VE, Herman B. Oxidative stress-induced apoptosis is associated with alterations in mitochondrial caspase activity and Bcl-2-dependent alterations in mitochondrial pH (pHm). Brain Res Bull 2004;62:497-504.
33. Dunaief JL, Dentchev T, Ying GS, Milam AH. The role of apoptosis in age-related macular degeneration. Arch Ophthalmol 2002;120:1435-1442.
34. Age-Related Eye Disease Study Research G. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-1436.
35. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000;45:115-134.
36. Cai J, Nelson KC, Wu M, Sternberg P Jr, Jones DP. Oxidative damage and protection of the RPE. Prog Retin Eye Res 2000;19:205-221.
37. Winkler BS, Boulton ME, Gottsch JD, Sternberg P. Oxidative damage and age-related macular degeneration. Mol Vis1999;5:32.
38. Justilien V, Pang JJ, Renganathan K, et al. SOD2 knockdown mouse model of early AMD. Invest Ophthalmol Vis Sci 2007;48:4407-4420.
39. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science 2005;308:421-424.
40. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A 2005;102:7227-7232.
41. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005;308:419-421.
42. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005;308:385-389.
43. Zareparsi S, Branham KE, Li M, et al. Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration. Am J Hum Genet 2005;77:149-153.
44. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006;19:361-372.
45. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-356.
46. Yi JJ, Ehlers MD. Ubiquitin and protein turnover in synapse function. Neuron 2005;47:629-632.
47. Gong B, Cao Z, Zheng P, et al. Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell 2006;126:775-788.
48. Feeney-Burns L, Berman ER, Rothman H. Lipofuscin of human retinal pigment epithelium. Am J Ophthalmol 1980;90:783-791.
49. Weiter JJ, Delori FC, Wing GL, Fitch KA. Retinal pigment epithelial lipofuscin and melanin and choroidal melanin in human eyes. Invest Ophthalmol Vis Sci 1986;27:145-152.
50. Kennedy CJ, Rakoczy PE, Constable IJ. Lipofuscin of the retinal pigment epithelium: a review. Eye 1995;9:763-771.
51. Dorey CK, Wu G, Ebenstein D, Garsd A, Weiter JJ. Cell loss in the aging retina. Relationship to lipofuscin accumulation and macular degeneration. Invest Ophthalmol Vis Sci 1989;30:1691-1699.
52. Katz ML, Gao CL, Rice LM. Formation of lipofuscin-like fluorophores by reaction of retinal with photoreceptor outer segments and liposomes. Mech Ageing Dev 1996;92:159-174.
53. Eldred GE. Age pigment structure. Nature 1993;364:396.
54. Eldred GE, Lasky MR. Retinal age pigments generated by self-assembling lysosomotropic detergents. Nature 1993;361:724-726.
55. Holz FG, Schutt F, Kopitz J, et al. Inhibition of lysosomal degradative functions in RPE cells by a retinoid component of lipofuscin. Invest Ophthalmol Vis Sci 1999;40:737-743.
56. Bergmann M, Schutt F, Holz FG, Kopitz J. Inhibition of the ATP-driven proton pump in RPE lysosomes by the major lipofuscin fluorophore A2-E may contribute to the pathogenesis of age-related macular degeneration. FASEB J 2004;18:562-564.
57. Boulton M, Dontsov A, Jarvis-Evans J, Ostrovsky M, Svistunenko D. Lipofuscin is a photoinducible free radical generator. J Photochem Photobiol B 1993;19:201-204.
58. Boulton M, Marshall J. Effects of increasing numbers of phagocytic inclusions on human retinal pigment epithelial cells in culture: a model for aging. Br J Ophthalmol 1986;70:808-815.
59. Davies S, Elliott MH, Floor E, et al. Photocytotoxicity of lipofuscin in human retinal pigment epithelial cells. Free Radic Biol Med 2001;31:256-265.
60. Godley BF, Shamsi FA, Liang FQ, Jarrett SG, Davies S, Boulton M. Blue light induces mitochondrial DNA damage and free radical production in epithelial cells. J Biol Chem 2005;280:21061-21066.
61. Kopitz J, Holz FG, Kaemmerer E, Schutt F. Lipids and lipid peroxidation products in the pathogenesis of age-related macular degeneration. Biochimie 2004;86:825-831.
62. Parish CA, Hashimoto M, Nakanishi K, Dillon J, Sparrow J. Isolation and one-step preparation of A2E and iso-A2E, fluorophores from human retinal pigment epithelium. Proc Natl Acad Sci U S A 1998;95:14609-14613.
63. Schutt F, Davies S, Kopitz J, Holz FG, Boulton ME. Photodamage to human RPE cells by A2-E, a retinoid component of lipofuscin. Invest Ophthalmol Vis Sci 2000;41:2303-2308.
64. Shamsi FA, Boulton M. Inhibition of RPE lysosomal and antioxidant activity by the age pigment lipofuscin. Invest Ophthalmol Vis Sci 2001;42:3041-3046.
65. Sparrow JR, Nakanishi K, Parish CA. The lipofuscin fluorophore A2E mediates blue light-induced damage to retinal pigmented epithelial cells. Invest Ophthalmol Vis Sci 2000;41:1981-1989.
66. Wassell J, Davies S, Bardsley W, Boulton M. The photoreactivity of the retinal age pigment lipofuscin. J Biol Chem 1999;274:23828-23832.
67. Boulton M, Rozanowska M, Rozanowski B. Retinal photodamage. J Photochem Photobiol B 2001;64:144-161.
68. Boulton M, Rozanowska M, Rozanowski B, Wess T. The photoreactivity of ocular lipofuscin. Photochem Photobiol Sci 2004;3:759-764.
69. Einbock W, Moessner A, Schnurrbusch UE, Holz FG, Wolf S. Changes in fundus autofluorescence in patients with age-related maculopathy. Correlation to visual function: a prospective study. Graefes Arch Clin Exp Ophthalmol 2005;243:300-305.
70. Feher J, Kovacs I, Artico M, Cavallotti C, Papale A, Balacco Gabrieli C. Mitochondrial alterations of retinal pigment epithelium in age-related macular degeneration. Neurobiol Aging 2006;27:983-993.
71. Holz FG, Bellmann C, Margaritidis M, Schutt F, Otto TP, Volcker HE. Patterns of increased in vivo fundus autofluorescence in the junctional zone of geographic atrophy of the retinal pigment epithelium associated with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1999;237:145-152.
72. Hopkins J, Walsh A, Chakravarthy U. Fundus autofluorescence in age-related macular degeneration: an epiphenomenon? Invest Ophthalmol Vis Sci 2006;47:2269-2271.
73. Hwang JC, Chan JW, Chang S, Smith RT. Predictive value of fundus autofluorescence for development of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci 2006;47:2655-2661.
74. Marmorstein AD, Marmorstein LY, Sakaguchi H, Hollyfield JG. Spectral profiling of autofluorescence associated with lipofuscin, Bruch's membrane, and sub-RPE deposits in normal and AMD eyes. Invest Ophthalmol Vis Sci 2002;43:2435-2441.
75. Smith RT, Chan JK, Busuoic M, Sivagnanavel V, Bird AC, Chong NV. Autofluorescence characteristics of early, atrophic, and high-risk fellow eyes in age-related macular degeneration. Invest Ophthalmol Vis Sci 2006;47:5495-5504.
76. Spaide RF. Fundus autofluorescence and age-related macular degeneration. Ophthalmology 2003;110:392-399.
77. Lois N, Owens SL, Coco R, Hopkins J, Fitzke FW, Bird AC. Fundus autofluorescence in patients with age-related macular degeneration and high risk of visual loss. Am J Ophthalmol 2002;133:341-349.
78. Schmitz-Valckenberg S, Bindewald-Wittich A, Dolar-Szczasny J, et al. Correlation between the area of increased autofluorescence surrounding geographic atrophy and disease progression in patients with AMD. Invest Ophthalmol Vis Sci 2006;47:2648-2654.
79. von Ruckmann A, Fitzke FW, Bird AC. Fundus autofluorescence in age-related macular disease imaged with a laser scanning ophthalmoscope. Invest Ophthalmol Vis Sci 1997;38:478-486.
80. Kim SR, Jang YP, Jockusch S, Fishkin NE, Turro NJ, Sparrow JR. The all-trans-retinal dimer series of lipofuscin pigments in retinal pigment epithelial cells in a recessive Stargardt disease model. Proc Natl Acad Sci U S A 2007;104:19273-19278.
81. Kim SR, He J, Yanase E, et al. Characterization of dihydro-A2PE: an intermediate in the A2E biosynthetic pathway. Biochemistry 2007;46:10122-10129.
82. Bellmann C, Holz FG, Schapp O, Volcker HE, Otto TP. [Topography of fundus autofluorescence with a new confocal scanning laser ophthalmoscope]. Ophthalmologe 1997;94:385-391.
83. von Ruckmann A, Fitzke FW, Bird AC. Distribution of fundus autofluorescence with a scanning laser ophthalmoscope. Br J Ophthalmol 1995;79:407-412.
84. Solbach U, Keilhauer C, Knabben H, Wolf S. Imaging of retinal autofluorescence in patients with age-related macular degeneration. Retina 1997;17:385-389.
85. Eldred GE, Katz ML. Fluorophores of the human retinal pigment epithelium: separation and spectral characterization. Exp Eye Res 1988;47:71-86.
86. Hammer M, Konigsdorffer E, Liebermann C, et al. Ocular fundus auto-fluorescence observations at different wavelengths in patients with age-related macular degeneration and diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2008;246:105-114.
87. McBain VA, Townend J, Lois N. Fundus autofluorescence in exudative age-related macular degeneration. Br J Ophthalmol 2007;91:491-496.
88. Holz FG, Bindewald-Wittich A, Fleckenstein M, Dreyhaupt J, Scholl HP, Schmitz-Valckenberg S. Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. Am J Ophthalmol 2007;143:463-472.
89. McBain VA, Townend J, Lois N. Fundus autofluorescence in exudative age-related macular degeneration. Br J Ophthalmol 2007;91:491-496.
90. Boulton M, Docchio F, Dayhaw-Barker P, Ramponi R, Cubeddu R. Age-related changes in the morphology, absorption and fluorescence of melanosomes and lipofuscin granules of the retinal pigment epithelium. Vision Res 1990;30:1291-1303.
91. Delori FC, Dorey CK, Staurenghi G, Arend O, Goger DG, Weiter JJ. In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci 1995;36:718-729.
92. Delori FC, Goger DG, Dorey CK. Age-related accumulation and spatial distribution of lipofuscin in RPE of normal subjects. Invest Ophthalmol Vis Sci 2001;42:1855-1866.
93. Feeney-Burns L, Hilderbrand ES, Eldridge S. Aging human RPE: morphometric analysis of macular, equatorial, and peripheral cells. Invest Ophthalmol Vis Sci 1984;25:195-200.
94. Rozanowska M, Pawlak A, Rozanowski B, et al. Age-related changes in the photoreactivity of retinal lipofuscin granules: role of chloroform-insoluble components. Invest Ophthalmol Vis Sci 2004;45:1052-1060.
95. Wing GL, Blanchard GC, Weiter JJ. The topography and age relationship of lipofuscin concentration in the retinal pigment epithelium. Invest Ophthalmol Vis Sci 1978;17:601-607.
96. Gray DA, Woulfe J. Lipofuscin and aging: a matter of toxic waste. Sci Aging Knowledge Environ 2005;2005:re1.
97. Feeney L. Lipofuscin and melanin of human retinal pigment epithelium. Fluorescence, enzyme cytochemical, and ultrastructural studies. Invest Ophthalmol Vis Sci 1978;17:583-600.
98. Feeney-Burns L, Gao CL, Berman ER. The fate of immunoreactive opsin following phagocytosis by pigment epithelium in human and monkey retinas. Invest Ophthalmol Vis Sci 1988;29:708-719.
99. Feeney-Burns L, Hilderbrand ES, Eldridge S. Aging human RPE: morphometric analysis of macular, equatorial, and peripheral cells. Invest Ophthalmol Vis Sci 1984;25:195-200.
100. Warburton S, Davis WE, Southwick K, et al. Proteomic and phototoxic characterization of melanolipofuscin: correlation to disease and model for its origin. Mol Vis 2007;13:318-329.
101. Berendschot TT, van Norren D. On the age dependency of the macular pigment optical density. Exp Eye Res 2005;81:602-609.
102. Malik KJ, Chen CD, Olsen TW. Stability of RNA from the retina and retinal pigment epithelium in a porcine model simulating human eye bank conditions. Invest Ophthalmol Vis Sci 2003;44:2730-2735.
103. Morimoto RI. Stress, aging, and neurodegenerative disease. N Engl J Med 2006;355:2254-2255.
104. Berliner JA, Subbanagounder G, Leitinger N, Watson AD, Vora D. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc Med 2001;11:142-147.
105. Berliner JA, Watson AD. A role for oxidized phospholipids in atherosclerosis. N Engl J Med 2005;353:9-11.
106. Leitinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipidol 2003;14:421-430.
107. Kaemmerer E, Schutt F, Krohne TU, Holz FG, Kopitz J. Effects of lipid peroxidation-related protein modifications on RPE lysosomal functions and POS phagocytosis. Invest Ophthalmol Vis Sci 2007;48:1342-1347.
108. Bartsch D, Freeman W. Scanning laser ophthalmoscopy. In: Ciulla T, Regillo C, Harris A, eds: Retina and Optic Nerve Imaging. Philadelphia: Lippincott Williams & Wilkins; 2003:59-76.
109. Johnson AC, Olsen TW, Marimanikkuppam SS, Ferrington DA. Identification and quantitation of lipofuscin fluorophores in human donor eyes. Poster presented at: ARVO Meeting; 2005; Fort Lauderdale, FL.